Boston Therapeutics Revenue, Profits - BTHE Annual Income Statement

Add to My Stocks
$0.05 $0.01 (25%) BTHE stock closing price Sep 20, 2018 (Closing)

Looking at financial statements, along with the Boston Therapeutics stock price, it's management, its economic moat, and industry competitors forms an important part of fundamental analysis. The key financial statements of a company are the income statement, the balance sheet and the cash flow statement. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue decrease to $- for 2017 impacts the BTHE stock. Investors typically check year over year or quarter over quarter revenue growth. The operating expenses as shown in the Boston Therapeutics profit and loss statement for 2017 total to $1.06M. This line item shows that the operating expenses has decreased compared with last year. Also check: Boston Therapeutics assets and Boston Therapeutics free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec201720162015201420132012201120102009
Boston Therapeutics Revenues or Net Sales
---------
Cost Of Goods Sold (COGS)---------
Boston Therapeutics Gross Profit
-0.02M--0.14M---0.01M---
Research & Development Expense---1.43M-----
Selling General & Admin Expense1.06M1.18M1.6M3.26M4.08M1.26M---
Income Before Depreciation Depletion Amortization-1.26M-1.26M-2.1M-4.67M-4.58M-1.46M-0.81M-0.24M-
Depreciation Depletion Amortization---------
Non Operating Income1.33M-0.52M-0.22M-0.01M-----
Interest Expense1.65M1.94M-------
Boston Therapeutics Pretax Income
-1.58M-3.73M-2.48M-4.69M-4.6M-1.48M-0.82M-0.24M-
Provision for Income Taxes---------
MinorityInterest---------
Investment Gains Losses---------
Other Income---------
Income Before Extraordinaries & Disc Operations-1.58M-3.73M-2.48M-4.69M-4.6M-1.48M-0.82M-0.24M-
Extraordinary Items & Discontinued Operations---------
Boston Therapeutics Profit/ Loss (Net Income)
-1.58M-3.73M-2.48M-4.69M-4.6M-1.48M-0.82M-0.24M-
Average Shares used to compute Diluted EPS51.47M43.54M39.11M38.19M25.37M16.87M15.15M10.7M-
Average Shares used to compute Basic EPS51.47M43.54M39.11M38.19M25.37M16.87M15.15M10.7M-
Income Before Nonrecurring Items-1.59M-3.74M-2.27M-4.7M-4.6M-1.48M-0.83M-0.25M-
Income from Nonrecurring Items---0.22M------
Boston Therapeutics Earnings Per Share Basic Net
-0.03-0.09-0.06-0.12-0.18-0.09-0.05-0.02-
Boston Therapeutics Earnings Per Share Diluted Net
-0.03-0.09-0.06-0.12-0.18-0.09-0.05-0.02-
EPS Diluted Before Nonrecurring Items-0.03-0.09-0.05-0.12-0.18-0.09-0.05-0.02-
Preferred Dividends Acc Pd---------
Dividends Common---------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Click here to view our Lexicon Pharma financial analysis

Boston Therapeutics stock analysis involves checking at least a few of the important things like:

  • Revenue: The money received by selling of goods or services comes under this line item. A YoY growth - See: Boston Therapeutics revenue chart implies that the company is growing. It has not been the case with Boston Therapeutics. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $-1.58M for BTHE stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called the profit and loss statement. Apart from the BTHE income statement, one can check the Boston Therapeutics historical stock prices to check how the price has moved with time.

Boston Therapeutics Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
92.05
Dividend Yield
0%

Annual Income Statements - Boston Therapeutics Inc Industry Peers

Biostar Pharma income statement, Integrated Biopharma income statement, Lexicon Pharma income statement